Some representative drugs, like osimertinib, the first and only targeted drug, are approved for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) T790M mutation [36]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.